Novartis AG Sponsored ADR (NVS)
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?
In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.
A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study
The Phase 3 study found a drug didn't reduce the risk of cardiovascular events like heart attacks and strokes.
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint
The company's shares declined in after-hours trading after the drug failed to reduce the risk of cardiovascular events in a Phase 3 study.
RBC backs Oxford BioMedica with 'outperform' rating amid Novartis trial halt
Oxford BioMedica PLC (LSE:OXB) received a reaffirmed 'outperform' rating from RBC Capital Markets on Friday, as the broker shrugged off clinical trial halts at two heavyweight pharmaceutical partners. The shares inched up 1% to 430p in morning trade, with RBC holding its 900p target price and branding the clinical disruption as of limited direct financial relevance.
This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One
Novartis just committed billions not to discover a new drug but to change how an existing one enters your body.
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Novartis' remibrutinib delivers positive phase III RMS results, reducing relapse rates versus Aubagio and supporting plans for global regulatory approvals.
Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trials
Panmure Liberum has maintained its 'buy' rating on Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, after its shares fell 15% following trial pauses by two of its customers. Novartis and Bristol Myers Squibb, both OXB customers, voluntarily paused enrolment in their autoimmune CAR-T programmes following safety issues.
Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping
Promising results from a recent clinical trial are boosting Novartis shares this morning.
Sandisk, Marvell, Robinhood, Novartis, Dell, and More Stocks That Explain Today's Market
AI stocks including Sandisk, Corning, and Intel struggle as investors ditch risk assets amid a run-up in bond yields.
Novartis' oral multiple sclerosis drug meets main goal in late stage studies
Swiss drugmaker Novartis said on Tuesday that its oral drug, remibrutinib, met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patients with a form of multiple sclerosis.
Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports
Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died, the Wall Street Journal reported on Tuesday.
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
Aktis Oncology (NASDAQ:AKTS) closed at $25.00 on August 18, 2026, giving the clinical-stage radiopharmaceutical company a market cap of $1.4 billion.
